JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller ... of adults with moderate-to-severe acute pain." CEO Dr. Reshma Kewalramani said Journavx was "the first ...

Vertex Pharmaceuticals' non-opioid painkiller received ... the treatment of adults with moderate-to-severe acute pain." CEO Dr. Reshma Kewalramani said Journavx was "the first new class of pain ...

Boston’s Museum of Science launched a yearlong series of programs exploring human interconnectivity that will feature Dr. Anthony Fauci, the former director of the National Institute of Allergy ...

Boston’s Museum of Science is launching a new yearlong program featuring former National Institute of Allergy and Infectious Diseases director Anthony Fauci, among others, the museum announced ...

The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex Pharmaceuticals ... milestone in acute pain management,” said Dr. Jacqueline Corrigan-Curay, acting director ...

Dr. Anthony Fauci will, among others, headline a new yearlong program at the Museum of Science in Boston focused on exploring “interconnectivity and the ways we can all better the lives we live ...

As with medical marijuana, Vertex Pharmaceuticals' new pain drug is ... pain and provides patients with another treatment option," Dr. Jacqueline Corrigan-Curay, acting director of the FDA's ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals ... In a statement, Dr. Jacqueline Corrigan-Curay, the acting director ...

Dr. Scott Ryan, MD works in Boston, MA as an Orthopedic Specialist and has 20 years experience. Dr. Ryan is board certified in Orthopedic Surgery and graduated from Tufts University in 2005.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...